SCHEMBL10312231

SCHEMBL10312231

C/C=C/c1cc(Nc2nc(/C=C/c3cccc(C(F)(F)F)c3)nc(N3CCOCC3)n2)n[nH]1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.49
USP2 O75604 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
IDH2 P48735 5/20 0.40
MAPT P10636 2/20 0.40
PIK3CA P42336 1/20 0.40
POLB P06746 2/20 0.38
TP53 P04637 1/20 0.38
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
APP P05067 1/20 0.36
KMT2A Q03164 1/20 0.36
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
RAF1 P04049 1/20 0.35
BRAF P15056 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16556933 0.93 HRH4 (0.51) HRH4USP2SMN1; SMN2IDH2MAPT
SCHEMBL10312230 0.91 IDH2 (0.52) HRH4USP2SMN1; SMN2IDH2MAPT
SCHEMBL10312234 0.91 HRH4 (0.61) HRH4USP2SMN1; SMN2IDH2MAPT
SCHEMBL10312075 0.90 USP2 (0.50) HRH4USP2SMN1; SMN2IDH2MAPT
SCHEMBL10312151 0.90 HRH4 (0.49) HRH4USP2SMN1; SMN2IDH2MAPT
SCHEMBL10312099 0.89 HRH4 (0.46) HRH4USP2SMN1; SMN2MAPTPIK3CA
SCHEMBL10312171 0.87 HRH4 (0.46) HRH4USP2MAPTPIK3CAPOLB
SCHEMBL16556849 0.87 MAPT (0.40) HRH4USP2SMN1; SMN2MAPTPOLB
SCHEMBL10312124 0.87 HRH4 (0.50) HRH4USP2SMN1; SMN2IDH2MAPT
SCHEMBL10312184 0.86 USP2 (0.46) HRH4USP2SMN1; SMN2IDH2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440055-B1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CALIFORNIA CAPITAL EQUITY LLC (US) 2015-03-11 EP disclosed
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS STK25, STK35, SGK2 HRH4 2393/4885USP2 1096/4885SMN1; SMN2 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.